Germany’s Origenis has entered into a global license and collaboration agreement with Expansion Therapeutics to research and discover small molecule compounds targeting RNA-mediated diseases.
The deal leverages the Origenis artificial intelligence (AI) discovery platform to identify drug development candidates for Expansion’s portfolio of RNA-targeted small molecule medicines.
Expansion will receive rights to develop products against defined molecular targets. Origenis will receive research payments and is eligible for certain development milestones.
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze